Randomized phase 2 trial comparing amrubicin (A) with re-challenge of platinum doublet (P) in patients (pts) with sensitive-relapsed small-cell lung cancer (SCLC)

Authors :: Toshiro Suzuki
Shingo Takanashi
Ichiro Kinoshita
Ryota Saito
Hiroshi Watanabe
Makoto Maemondo
Naoto Morikawa
Satoshi Oizumi
Takashi Ishida
Toshihiro Nukiwa
Taku Nakagawa
Akira Inoue
Atsushi Nakamura
Masao Harada
Yoshiaki Mori
Source :: Journal of Clinical Oncology. 32:7520-7520
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 7520 Background: When this trial was planned, A was believed to be a promising new anthracycline agent for sensitive-relapsed SCLC. While re-challenge of P that had been used for the first-line tre...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Anthracycline
business.industry
respiratory tract diseases
Surgery
Internal medicine
medicine
Re challenge
In patient
business
Relapsed Small Cell Lung Cancer
Amrubicin

Tools